A phase III trial of PPP001 (smokeable marijuana) in terminal cancer patients

Trial Profile

A phase III trial of PPP001 (smokeable marijuana) in terminal cancer patients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Marijuana (Primary)
  • Indications Cancer pain; Neuropathic pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Tetra Bio Pharma
  • Most Recent Events

    • 04 Apr 2018 According to a Tetra Bio Pharma media release, this trial will be used o support the marketing application of PPP001 smokable pellet that is followed by four other cannabinoid-based products that we are developing using different delivery systems such as oral tablets, eye drops, topical ointments and oral capsules of cannabis oil.
    • 04 Apr 2018 Status changed from planning to recruiting, according to the Tetra Bio Pharma media release.
    • 05 Feb 2018 According to a Tetra Bio Pharma media release, based on the positive data of this trial, the company will submit a filing for a Drug Identification Number (DIN) to Health Canada in 2019 as a new noninvasive treatment to relieve pain for cancer patient.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top